Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad. Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets. Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas. The key therapeutic areas include cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics and dermatology products in dosage forms such as injectables, tablets, capsules, liquid orals and ointments. The Company acquired Unit-I and Unit-II in 2016. It launched Prefilled technology equipment at Unit-I in FY 2021. Company has undertaken strategic acquisitions that expanded the manufacturing, technological and CDMO capabilities, diversified the product range and increased geographical presence in regulated and semi regulated markets. In February 2022, Company acquired Unit III facility located at IDA Bhongir, Hyderabad and accredited by the Therapeutic Goods Administration (TGA), Australia. In September 2022, Company acquired Unit IV facility accredited with Pharmaceutical Inspection Co-operation Scheme (PIC/S) and WHO-GMP. It started the export business in 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. In February 2024, Company further expanded its domestic presence by making Revat Laboratories as a wholly owned subsidiary. The Company has incorporated a wholly owned subsidiary, Sai Parenterals Pte. Limited in Singapore in FY25. Company is planning the Initial Public Offer by issuing 3,500,000 equity shares having the face value of Rs 5 each through Offer for Sale and by raising Rs 285 Cr equity shares through Fresh Issue.